Log In
Print
BCIQ
Print
Print this Print this
 

Mylotarg, gemtuzumab ozogamicin

Also known as: CMA-676

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionCombination of calicheamicin with a humanized mAb that targets CD33-expressing cancer cells
Molecular Target CD33
Mechanism of ActionAntibody-drug conjugate
Latest Stage of DevelopmentMarketed
IndicationAcute myelogenous leukemia (AML)
Partner

UCB Group
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today